Selank and Semax come up together constantly, two peptides out of the same Russian research tradition, both pitched for the brain. Here's how researchers actually distinguish them, minus the forum hype.

Common roots, different emphasis

Both were developed in Russia and studied largely there. The rough split: Selank's research centers more on anxiety, while Semax has been studied more for cognition, attention, and neuroprotection (in Russia it carries approvals for certain neurological indications). Neither is FDA-approved in the US.

Proposed mechanisms (hedged)

Researchers have proposed that Selank may influence systems involved in mood, and that Semax may affect signaling related to learning and neuroprotection. These are areas of investigation drawn from mostly early and regional research, not settled facts.

Same regulatory boat

Both were swept into the FDA's 2023 peptide restriction. In the 2026 reassessment, the July advisory-committee agenda includes Semax but not Selank, though neither is FDA-approved and both remain unsettled. See 2026 Updates.

Selank leans anxiety, Semax leans cognition, but both lean heavily on early, mostly unreplicated research.

Bottom line

For the full picture, see our Selank article and Semax guide, and talk to a licensed provider before considering anything. For anxiety specifically, evidence-based care comes first.